Viropharma halts maribavir Phase III trial in liver transplant patients
This article was originally published in Scrip
Executive Summary
ViroPharma has discontinued a 348-patient Phase III trial of its antiviral maribavir as prophylaxis for cytomegalovirus (CMV) disease in liver transplant patients, and all patients receiving the study drug will be moved to the current standard of care. The decision was based on the recent failure of another Phase III trial of maribavir in stem cell transplant patients, and a recommendation from the trial's independent data monitoring committee (ScripOnline, February 12th, 2009). Maribavir is not in clinical trials for any other indications.